Oral HRS-7535 Lowered A1c in Trial - Summary - MDSpire

Oral HRS-7535 Lowered A1c in Trial

Nonpeptide oral agent requires no fasting administration.

  • By

  • Kathryn Wighton

  • June 5, 2026

  • 9 min

Share

Objective:

To evaluate the efficacy of once-daily oral HRS-7535 in reducing hemoglobin A1c levels in patients with type 2 diabetes inadequately controlled with metformin, particularly focusing on the demographic characteristics of the population.

Key Findings:
  • HRS-7535 reduced hemoglobin A1c levels significantly compared to placebo, with reductions of 1.19% to 1.82% across different doses (p < 0.05).
  • 49% to 63% of patients on HRS-7535 achieved hemoglobin A1c levels below 7.0%, compared to 15% in the placebo group (p < 0.05).
  • Rescue antihyperglycemic therapy was required in 3% to 8% of patients receiving HRS-7535, compared to 31% in the placebo group (p < 0.05).
  • Gastrointestinal adverse events were common, with nausea occurring in 8% to 34% of patients on HRS-7535.
Interpretation:

The study demonstrated statistically significant reductions in hemoglobin A1c with HRS-7535 in the studied population, suggesting potential benefits for clinical practice, although caution is advised in generalizing results to other populations.

Limitations:
  • The trial duration of 16 weeks may not fully capture long-term glycemic responses.
  • The study population had a mean body mass index of 26.7, which may not represent higher BMI populations in Western countries, potentially affecting generalizability.
  • No formal adjustment for multiplicity was applied, necessitating cautious interpretation of secondary endpoints.
Conclusion:

HRS-7535 shows promise in lowering A1c levels in type 2 diabetes patients, but further studies are needed to confirm efficacy and safety, particularly in diverse populations.

Original Source(s)

Oral HRS-7535 Lowered A1c in Trial

  • by Kathryn Wighton

  • June 5, 2026

Related Content

Prolonged Sleep Restriction May Increase Body Weight

In a pooled analysis of two randomized crossover trials, reducing nightly sleep by about 1.5 hours for 6 weeks was associated with modest increases in body weight and waist circumference without measurable changes in body composition.

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

Combo Therapy May Improve HbA1c in Type 2 Diabetes

Oral orforglipron could be more effective in reducing hemoglobin A1c and body weight, with no increased risk of hypoglycemia in patients with inadequately controlled type 2 diabetes.